Quantitative PET analyses of regional [11C]PE2I binding to the dopamine transporter — Application to juvenile myoclonic epilepsy

The dopamine transporter (DAT) is of central interest in research on the pathophysiology and treatment of neuro-psychiatric disorders. [(11)C]PE2I is an established radioligand that provides high-contrast delineation of brain regions that are rich in DAT. The aim of the present PET study in eight patients with juvenile myoclonic epilepsy (JME) was to evaluate the kinetics of [(11)C]PE2I in the brain and to compare binding parameters with those of age-matched control subjects (n = 6). Each patient participated in 90-minute PET measurements with [(11)C]PE2I. Data were analyzed using kinetic compartment analyses with metabolite-corrected arterial plasma input and reference tissue models using the cerebellum as a reference region. The time-activity curves were well described by the two-tissue compartment model (2TCM) for the DAT-rich regions. The 2TCM with fixed K(1)/k(2) ratio derived from the cerebellum provided robust and reliable estimates of binding potential (BP(ND)) and total distribution volume (V(T)). The reference tissue models also provided robust estimates of BP(ND), although they gave lower BP(ND) values than the kinetic analysis. Compared with those of control subjects, we found that BP(ND) values obtained by all approaches were reduced in the midbrain of the patients with JME. The finding indicates impaired dopamine uptake in the midbrain of JME patients. The three-tissue compartment model could best describe uptake in the cerebellum, indicating that two kinetically distinguishable compartments exist in cerebellar tissue, which may correspond to nonspecific binding and the blood-brain barrier passing metabolite. The reference tissue models should be applied with better understanding of the biochemical nature of the radioligand and the reliability of these approaches.

[1]  J. Swanson,et al.  Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: Therapeutic implications , 2002, Synapse.

[2]  I. Kanno,et al.  Quantitative analysis of dopamine transporters in human brain using [11C]PE2I and positron emission tomography: evaluation of reference tissue models , 2010, Annals of nuclear medicine.

[3]  M. Bannon,et al.  Valproate robustly increases Sp transcription factor‐mediated expression of the dopamine transporter gene within dopamine cells , 2007, The European journal of neuroscience.

[4]  Christine DeLorenzo,et al.  Modeling Considerations for In Vivo Quantification of the Dopamine Transporter using [11C]PE2I and Positron Emission Tomography , 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[5]  C. Halldin,et al.  Pet study of [11C] β‐CIT binding to monoamine transporters in the monkey and human brain , 1994, Synapse.

[6]  W H Theodore,et al.  Effect of Valproate on Cerebral Metabolism and Blood Flow: An 18F‐2‐Deoxyglusose and 15O Water Positron Emission Tomography Study , 1996, Epilepsia.

[7]  A. Gjedde,et al.  Quantification of Neuroreceptors in the Living Human Brain. I. Irreversible Binding of Ligands , 1986, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[8]  D Guilloteau,et al.  Synthesis and ligand binding of nortropane derivatives: N-substituted 2beta-carbomethoxy-3beta-(4'-iodophenyl)nortropane and N-(3-iodoprop-(2E)-enyl)-2beta-carbomethoxy-3beta-(3',4'-disubstituted phenyl)nortropane. New high-affinity and selective compounds for the dopamine transporter. , 1997, Journal of medicinal chemistry.

[9]  Sabine Rona,et al.  Chronic High‐Frequency Deep Brain Stimulation of the STN/SNr for Progressive Myoclonic Epilepsy , 2007, Epilepsia.

[10]  C. Halldin,et al.  [11C] beta-CIT, a cocaine analogue. Preparation, autoradiography and preliminary PET investigations. , 1993, Nuclear medicine and biology.

[11]  S. Hong,et al.  CBF changes in drug naive juvenile myoclonic epilepsy patients , 2007, Journal of Neurology.

[12]  C. Halldin,et al.  Quantitative analyses of carbonyl-carbon-11-WAY-100635 binding to central 5-hydroxytryptamine-1A receptors in man. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  C. Kilts,et al.  18F-labeled FECNT: a selective radioligand for PET imaging of brain dopamine transporters. , 2000, Nuclear medicine and biology.

[14]  L. Farde,et al.  Kinetic Analysis of Central [11C]Raclopride Binding to D2-Dopamine Receptors Studied by PET—A Comparison to the Equilibrium Analysis , 1989, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[15]  D. Wong,et al.  In vivo imaging of baboon and human dopamine transporters by positron emission tomography using [11C]WIN 35,428 , 1993, Synapse.

[16]  C. Halldin,et al.  Pharmacological Characterization of (E)-N-(4-Fluorobut-2-enyl)-2β-carbomethoxy-3β-(4′-tolyl)nortropane (LBT-999) as a Highly Promising Fluorinated Ligand for the Dopamine Transporter , 2006, Journal of Pharmacology and Experimental Therapeutics.

[17]  Yuan-Hwa Chou,et al.  [11C]PE2I: a highly selective radioligand for PET examination of the dopamine transporter in monkey and human brain , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[18]  D. Guilloteau,et al.  Visualization of the Dopamine Transporter in the Human Brain Postmortem with the New Selective Ligand [125I]PE2I , 1999, NeuroImage.

[19]  B. Gulyás,et al.  In vitro autoradiography and in vivo evaluation in cynomolgus monkey of [18F]FE‐PE2I, a new dopamine transporter PET radioligand , 2009, Synapse.

[20]  J. Edinger,et al.  Reversible parkinsonism and cognitive impairment with chronic valproate use , 1996, Neurology.

[21]  A. Lammertsma,et al.  Simplified Reference Tissue Model for PET Receptor Studies , 1996, NeuroImage.

[22]  Roger N. Gunn,et al.  Tracer Kinetic Modeling of the 5-HT1AReceptor Ligand [carbonyl-11C]WAY-100635 for PET , 1998, NeuroImage.

[23]  Yuan-Hwa Chou,et al.  [(11)C]PE2I: a highly selective radioligand for PET examination of the dopamine transporter in monkey and human brain. , 2003, European journal of nuclear medicine and molecular imaging.

[24]  S. Amara,et al.  Dynamic regulation of the dopamine transporter. , 2003, European journal of pharmacology.

[25]  Christer Halldin,et al.  Radioligand Disposition and Metabolism — Key Information in Early Drug Development , 1995 .

[26]  T. Greitz,et al.  Head fixation device for reproducible position alignment in transmission CT and positron emission tomography. , 1981, Journal of computer assisted tomography.

[27]  J J DiStefano,et al.  Multiexponential, multicompartmental, and noncompartmental modeling. II. Data analysis and statistical considerations. , 1984, The American journal of physiology.

[28]  F. Fazio,et al.  The status of dopamine nerve terminals in Parkinson's disease and essential tremor: a PET study with the tracer [11-C]FE-CIT , 2001, Neurological Sciences.

[29]  Sylvain Houle,et al.  Lower dopamine transporter binding potential in striatum during depression , 2001, Neuroreport.

[30]  J. Seidel,et al.  Identification and regional distribution in rat brain of radiometabolites of the dopamine transporter PET radioligand [11C]PE2I , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[31]  A. Hill,et al.  The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves , 1910 .

[32]  Sylvain Houle,et al.  Positron Emission Tomography Quantification of [11C]-Harmine Binding to Monoamine Oxidase-A in the Human Brain , 2006, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[33]  Carolina Ciumas,et al.  The dopamine system in idiopathic generalized epilepsies: Identification of syndrome-related changes , 2010, NeuroImage.

[34]  K. Gale,et al.  Subcortical structures and pathways involved in convulsive seizure generation. , 1992, Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society.

[35]  Martin McKee,et al.  Environmental Profile of a Community's Health (EPOCH): An Instrument to Measure Environmental Determinants of Cardiovascular Health in Five Countries , 2010, PloS one.

[36]  N. Volkow,et al.  Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[37]  C. Greer,et al.  Mediation of myoclonic seizures by dopamine and clonic seizures by acetylcholine and GABA. , 1977, Life sciences.

[38]  C. Halldin,et al.  Molecular Imaging of the Dopamine Transporter , 2010, The Journal of Nuclear Medicine.

[39]  G. Schwarz Estimating the Dimension of a Model , 1978 .

[40]  C. Deransart,et al.  The control of seizures by the basal ganglia? A review of experimental data. , 2002, Epileptic disorders : international epilepsy journal with videotape.

[41]  C. Halldin,et al.  Reduced dopamine transporter binding in patients with juvenile myoclonic epilepsy , 2008, Neurology.

[42]  T. Jiang,et al.  Cerebellum Abnormalities in Idiopathic Generalized Epilepsy with Generalized Tonic-Clonic Seizures Revealed by Diffusion Tensor Imaging , 2010, PloS one.

[43]  Christer Halldin,et al.  [18F]Flumazenil binding to central benzodiazepine receptor studies by PET – Quantitative analysis and comparisons with [11C]flumazenil – , 2009, NeuroImage.

[44]  D. Guilloteau,et al.  Synthesis and Ligand Binding of Nortropane Derivatives: N‐Substituted 2β‐Carbomethoxy‐3β‐(4′‐iodophenyl)nortropane and N‐(3‐ Iodoprop‐(2E)‐enyl)‐2β‐carbomethoxy‐3β‐(3′,4′‐disubstituted phenyl)nortropane. New High‐Affinity and Selective Compounds for the Dopamine Transporter. , 1997 .

[45]  Christer Halldin,et al.  Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/hyperactivity disorder: Association between striatal dopamine markers and motor hyperactivity , 2005, Biological Psychiatry.

[46]  D. Comar,et al.  PET for drug development and evaluation , 1995 .

[47]  Ivanka Savic,et al.  Structural changes in patients with primary generalized tonic and clonic seizures , 2006, Neurology.

[48]  M. Mintun,et al.  A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography , 1984, Annals of neurology.

[49]  C. Halldin,et al.  Quantification of 11C-MADAM binding to the serotonin transporter in the human brain. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[50]  H. Akaike A new look at the statistical model identification , 1974 .

[51]  G. Sedvall,et al.  PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. , 1997, Brain : a journal of neurology.

[52]  Harumasa Takano,et al.  Increase in thalamic binding of [(11)C]PE2I in patients with schizophrenia: a positron emission tomography study of dopamine transporter. , 2009, Journal of psychiatric research.

[53]  Christer Halldin,et al.  Quantitative analyses of regional [11C]PE2I binding to the dopamine transporter in the human brain: a PET study , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[54]  Claude Comtat,et al.  Assessment of 11C-PE2I Binding to the Neuronal Dopamine Transporter in Humans with the High-Spatial-Resolution PET Scanner HRRT , 2007, Journal of Nuclear Medicine.

[55]  Merja Haaparanta,et al.  Decreased striatal dopamine transporter binding in vivo in chronic schizophrenia , 2001, Schizophrenia Research.

[56]  Christer Halldin,et al.  Measurement of Striatal and Extrastriatal Dopamine Transporter Binding with High-Resolution PET and [11C]PE2I: Quantitative Modeling and Test—Retest Reproducibility , 2008, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[57]  J. M. Ollinger,et al.  Positron Emission Tomography , 2018, Handbook of Small Animal Imaging.

[58]  R. P. Maguire,et al.  Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[59]  K. Zilles,et al.  Human brain atlas: For high‐resolution functional and anatomical mapping , 1994, Human brain mapping.

[60]  I. Alafuzoff,et al.  Loss of dopamine uptake sites labeled with [3H]GBR-12935 in Alzheimer's disease. , 1990, European neurology.

[61]  Roger N. Gunn,et al.  Tracer Kinetic Modelling of the 5-HT1A Receptor Ligand [carbonyl-11C]WAY-100635 , 1998, NeuroImage.

[62]  A. Gjedde,et al.  Dopamine transporter changes in neuropsychiatric disorders. , 1998, Advances in pharmacology.

[63]  J S Fowler,et al.  Kinetic Modeling of Receptor‐Ligand Binding Applied to Positron Emission Tomographic Studies with Neuroleptic Tracers , 1987, Journal of neurochemistry.

[64]  Christer Halldin,et al.  [11C]β‐CIT‐FE, a radioligand for quantitation of the dopamine transporter in the living brain using positron emission tomography , 1996 .